



## **Helius Medical Technologies, Inc. to Present at the Investor Summit Group's Q1 Virtual Summit on March 23rd**

**March 17, 2021 12:00 PM EDT**

NEWTOWN, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced that management will participate in the Investor Summit Group's Q1 Virtual Summit, which is being held from March 23th-25th. Management will present on Tuesday, March 23th at 2:00 p.m. Eastern Time.

A live audio webcast of the conference presentation will be available on the Noble conference website following free registration: <https://www.nobleconference.com/register/investor-guest>. An archive of the webcast will be available following the conference under the 'Events' section of the Helius Medical Technologies investor relations website at <https://heliusmedical.com/index.php/investor-relations/events/upcoming-events>.

### **About Helius Medical Technologies, Inc.**

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit [www.heliusmedical.com](http://www.heliusmedical.com).

### **About the PoNS™ Device and PoNS Treatment™**

The Portable Neuromodulation Stimulator (PoNS™) is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from multiple sclerosis (MS), and chronic balance deficit due to mild-to-moderate traumatic brain injury (mTBI) and is to be used in conjunction with physical therapy. The PoNS™ is an investigational medical device in the United States, the European Union ("EU"), and Australia ("AUS"). The device is currently under review for clearance by the FDA. It is also under premarket review by the AUS Therapeutic Goods Administration. PoNS™ is currently not commercially available in the United States, the European Union or Australia.

### **Investor Relations Contact:**

Westwicke on behalf of Helius Medical Technologies, Inc.  
Jack Powell, Vice President  
[investorrelations@heliusmedical.com](mailto:investorrelations@heliusmedical.com)